Fig. 3.
A: representative pressure-volume loops from each treatment group. B and C: efficacy of plain drugs or formulations in improving cardiac functional parameters: cardiac index (B) and total pulmonary vascular resistance (C). Data represent means ± SE. IT, intratracheal; LV, left ventricle; MP, microparticles; Ros, rosiglitazone; Sil, sildenafil. Data were analyzed using one-way ANOVA followed by Fisher’s least significant difference test; n = 3–4, *P < 0.05.